#USA #Rockville #gene therapy #Clinical Trials #REGENXBIO

REGENXBIO Reports Financial Results and Operational Highlights for Q2 2025

On August 7, 2025, REGENXBIO Inc. (Nasdaq RGNX) provided an insightful overview of its financial performance and notable operational advancements for the second quarter ending June 30, 2025. This report showcases their commitment to developing innovative gene therapies that aim to transform the treatment landscape for serious diseases, particularly Duchenne muscular dystrophy (Duchenne), MPS II, and chronic retinal diseases.

Key Developments

One of the most significant updates is the progress of RGX-202, a gene therapy targeting Duchenne muscular dystrophy, with expectations to present topline results in the first half of 2026 followed by a Biologics License Application (BLA) submission mid-year. The pivotal trial, designed to assess the efficacy of RGX-202, has seen accelerated enrollment, with an expected completion by October 2025.

Along with RGX-202, REGENXBIO is advancing its clemidsogene lanparvovec (RGX-121) initiative for MPS II, designed to be the first-ever gene therapy for the condition. The company's manufacturing facilities have successfully passed FDA inspections, highlighting REGENXBIO's preparedness for potential commercialization.

In the realm of retinal diseases, REGENXBIO's surabgene lomparvovec (sura-vec) is on track to become the first gene therapy approved for chronic retinal diseases, with pivotal clinical trial data anticipated next year. These trials are particularly focused on the effectiveness of sura-vec in treating wet age-related macular degeneration (AMD) and diabetic retinopathy (DR).

Financial Highlights

Financially, the company reported $21.4 million in revenues for the second quarter, a slight decrease from the previous year attributed to a drop in Zolgensma royalties. Nevertheless, service revenues increased, bolstered by collaborations such as that with Nippon Shinyaku, which contributed to REGENXBIO's cash reserves reaching $363.6 million as of June 30, 2025.

Operating expenses for R&D were $59.5 million, reflecting higher costs associated with pivotal trials for RGX-202 and sura-vec. Despite noting an increase in net loss to $70.9 million from $53.0 million reported last year, the company remains optimistic about the future, projecting that their current cash position will sustain operations until early 2027.

Looking Ahead

With promising data spurring further advancements, REGENXBIO plans to announce topline results for RGX-202 in its ongoing trials in 2026, with an eventual market launch anticipated in 2027. These developments underscore REGENXBIO's determination to enhance treatment options through innovative gene therapies aimed at addressing significant unmet medical needs.

In a broader industry context, REGENXBIO remains at the forefront of gene therapy, committed to reshaping healthcare and offering curative treatments for rare and complex diseases. Interested stakeholders are invited to participate in the upcoming conference call to gain further insights into REGENXBIO’s strategic initiatives and developmental roadmap.